(Q36058502)

11 August 2017

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia (English)

1 reference

11 August 2017

phase I clinical trial

0 references

1 reference

2

Martin S Tallman

1 reference

11 August 2017

3

Tadeusz Robak

1 reference

Maryalice Stetler-Stevenson

11 August 2017

series ordinal

6

object named as

Maryalice Stetler-Stevenson

1 reference

11 August 2017

5

Wyndham H Wilson

1 reference

11 August 2017

1

Robert J Kreitman

1 reference

11 August 2017

9

Ira Pastan

1 reference

11 August 2017

Steven Coutre

4

1 reference

11 August 2017

David J Fitzgerald

series ordinal

7

1 reference

11 August 2017

Robert Lechleider

series ordinal

8

1 reference

11 August 2017

language of work or name

English

0 references

publication date

21 February 2012

1 reference

Journal of Clinical Oncology

11 August 2017

1 reference

11 August 2017

30

1 reference

11 August 2017

15

1 reference

11 August 2017

1822-1828

1 reference

Thrombotic microangiopathy with targeted cancer agents

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Modern strategies for hairy cell leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Hairy cell leukemia: towards a curative strategy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Pentostatin: impact on outcome in hairy cell leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Extended follow-up of patients with hairy cell leukemia after treatment with cladribine

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383181

2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia

23 September 2018

1 reference

12 December 2020

A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission

1 reference

12 December 2020

Disease eradication in hairy cell leukemia patients treated with 2-chlorodeoxyadenosine

1 reference

12 December 2020

Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience

1 reference

12 December 2020

Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up

1 reference

12 December 2020

Long-term follow-up of patients with hairy cell leukemia after cladribine treatment

1 reference

12 December 2020

Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse

1 reference

12 December 2020

Leukemic reticuloendotheliosis

1 reference

12 December 2020

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies

1 reference

12 December 2020

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

1 reference

12 December 2020

1 reference

12 December 2020

Responses in refractory hairy cell leukemia to a recombinant immunotoxin

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2011.38.1756

1 reference

release_xmwz4rel5nhixkkslmraogywvu

11 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xmwz4rel5nhixkkslmraogywvu

24 November 2022

mapped directly with Wikidata item

1 reference

11 August 2017

PubMed publication ID

22355053

1 reference